How GLP-1 is impacting food and beverage consumption in Australia

GLP-1 receptor drugs are rapidly becoming one of the most influential health innovations of the past decade. Originally developed to treat type-2 diabetes, they are now widely prescribed for weight management due to their ability to suppress appetite and increase feelings of fullness.

In Australia, uptake is accelerating quickly. Estimates suggest around half a million Australians are already using GLP-1 medications for weight management or diabetes treatment. Current projections suggest up to 10 per cent of the population could be on GLP-1 therapies by 2030.

Given that around one-third of Australians live with obesity, these medications have the potential to influence dietary patterns across a significant portion of the population. This, combined with overarching healthy diet goals observed in the recent Focus Insights Grocery Shopper Report, where we saw statements on the importance of healthy eating and the availability of healthy options rated at greater than 75 per cent of respondent agreement, reinforces the idea that these are trends that cannot be ignored.

How GLP-1 drugs change eating behaviour

The impact of GLP-1 drugs on food consumption is primarily physiological, where these medications mimic a natural hormone that regulates hunger, digestion and satiety. They work by suppressing appetite and reducing hunger signals, increasing feelings of fullness and reducing cravings for high-calorie foods and alcohol.

These effects lead to significantly lower calorie intake and altered food preferences. Many users report they no longer think about food as frequently, and external cues such as smell or advertising become less influential on their consumption behaviour.

Early evidence of changing consumption of food and beverages

Early market data already shows measurable effects on grocery behaviour and food demand. Key emerging patterns include:

1. Lower overall food consumption: Households with at least one GLP-1 user have been shown to reduce grocery spending by around 6 per cent within six months of starting treatment.

2. Decline in high-calorie discretionary foods: Consumption tends to fall most strongly in categories such as snack foods (chips, confectionery), sugary drinks, and highly processed foods.

3. Increased demand for nutrient-dense foods: Users are shifting toward protein-rich foods, fresh produce and smaller but higher-quality foods.

Industry analysts expect appetite suppression to shift demand toward protein-rich and nutrient-dense products over time. Consistent with these trends are reported shifts in category buying from Australians over the last year from the Focus Insights Grocery Shopper Report, with noticeable drops for snacks, treats and confectionery, alcohol and non-alcoholic beverages, and rises seen for households saying they are buying more fresh fruit and vegetables, dairy and eggs and health and wellness products in general.

The ‘quality over quantity’ consumption shift

One of the most interesting emerging patterns is the move from quantity to quality. GLP-1 users tend to:

Eat smaller portions.
Choose more nutritious foods.
Occasionally purchase premium indulgences in smaller amounts.

This shift has been described as the emergence of ‘appetite economics’ – where consumption declines in size, but the perceived value of each occasion increases.

The potential macro impact on the food and beverage industry

For food manufacturers and retailers, the long-term implications include:

Smaller average meal sizes.
Reduced snacking frequency.
Greater focus on nutrition density.
Reformulation of products to increase protein or fibre content.

For the Australian food and beverage sector, GLP-1 adoption could trigger structural changes similar to previous health-driven shifts, such as the low-fat movement of the 1990’s, the sugar-reduction trend of the 2010’s, and the protein and functional food boom of the 2020’s.

The key difference is that GLP-1 drugs directly alter appetite physiology, rather than simply influencing consumer attitudes. For FMCG brands and retailers, the strategic implications include:

Smaller packs, snack formats and portion control.
Nutrition innovation with products that deliver more protein, fibre, or functional benefits per serve.
Premiumisation, where consumers trade down in quantity but up in quality.
The shopper journey changes with reduced impulse purchasing and a lower snacking frequency.

The future outlook

While still early, GLP-1 medications may represent one of the largest long-term disruptors to the global food industry, likely to transform the relationship consumers have with food, shifting from quantity and impulse toward more intentional, higher-value eating occasions.

Key takeaway

GLP-1 medications are not simply a healthcare innovation – they are emerging as a structural shift in demand for the global food system. For Australian FMCG companies, the real opportunity lies not in resisting this change, but in designing and testing products for a world where ‘every bite counts’.